Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1240)	7/21/1999 11:42:00 PM
From: Vector1	Read Replies (1) \| Respond to of 1826

<<Thus we have an excellent earnings report apparently greeted by disappointment.>> Peter, Looks to me like Salagen sales increased sequentially from $4.3m to $4.6m or about 7%. I was hoping for 15% quarter to quarter growth. V1

To: Biomaven who wrote (1240)	7/22/1999 1:02:00 AM
From: Russian Bear	Read Replies (1) \| Respond to of 1826

Peter, I have to agree with you about the importance of under-promising and over-delivering. Luckily, it appears that management is doing just that. As far as certain folks on the Yahoo! thread pitching MOGN too aggressively, I doubt that it makes any difference, one way or the other. I doubt that any of them can have a substantive effect on the price of the stock of a $150 - $200 Million company, at least not in this sector (now, in the i-net stocks...) Rick, I was certainly among those who were secretly hoping for a substantive update on 114. That is not to say that I was disappointed in today's earnings report, by any means. On the contrary, the progress being demonstrated with the core pharma business is outstanding. At this market cap., the entire MGI-114 program is an absolute "freebie," and the risk of investment has never been lower, in my judgement. If I weren't faced with the dual nuisances of having only limited capital and being tormented/tempted by an $18-and-change GLIA, I would be adding more shares to my already-too-large position, hand over fist. <g> Stray thoughts: I would categorize the conference call as being highly informative and encouraging. Financial performance going forward should continue to be strong. Venturing to "read between the lines" of some of the answers given to questions regarding the progress of 114 (admittedly, a dangerous practice,) I am forming a moderately optimistic picture of the clinical situation. Accrual into the trials appears to continue to be on the slow side, however. On a lighter note, it is certainly nice to see so many of SI/biotech's "heavy hitters" posting here, today/tonight. RB